A Study of Participants in Australia Who Have Non-small Cell Lung Cancer Being Treated With Nivolumab
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Other: Non-Interventional
- Registration Number
- NCT03804554
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
This study is to capture and describe the patient and disease characteristics and the outcomes of adult patients with previously-treated advanced NSCLC who have been treated with Nivolumab
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 503
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
- Insufficient data available
Other protocol defined inclusion/exclusion criteria could apply
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients taking nivolumab Non-Interventional -
- Primary Outcome Measures
Name Time Method Time to treatment failure (TTF) Approximately 27 months
- Secondary Outcome Measures
Name Time Method Incidence of SAE's Approximately 27 months Incidence of re-treatment Approximately 27 months Progression free survival rate (PFSR) Approximately 27 months Incidence of AE's Approximately 27 months Best overall response (BOR) Approximately 27 months Overall survival rate (OSR) Approximately 27 months Reasons for ceasing treatment Approximately 27 months Any of the following: progressive disease, toxicity, patient wishes/preference, doctor decision, death
Incidence of patients with brain metastases Approximately 27 months
Trial Locations
- Locations (1)
Local Institution
🇦🇺Heidelburg, Victoria, Australia